Evidence map›Paper›PMID 41152498›Full record

ArticleScientific reports2025

In vitro, in silico, and DFT evaluation of antimicrobial imidazole derivatives with insights into mechanism of action.

Nargiz S Orujova, Vagif M Abbasov, Rana A Jafarova, Ayaz M Mammadov, Imren Bayil, Sevda A Muradova, Nabila Djadi, Taha Alqahtani, Al-Anood M Al-Dies, Yayesew Amlaku Zerihun and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Frontiers in bioinformatics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nargiz S OrujovaAcademician Y.H. Mammadaliyev Institute of Petrochemical Processes of the Ministry of Science and Education of the Republic of Azerbaijan, AZ 1025, 30 Khojaly str., Baku, Azerbaijan.
Vagif M AbbasovAcademician Y.H. Mammadaliyev Institute of Petrochemical Processes of the Ministry of Science and Education of the Republic of Azerbaijan, AZ 1025, 30 Khojaly str., Baku, Azerbaijan.
Rana A JafarovaAcademician Y.H. Mammadaliyev Institute of Petrochemical Processes of the Ministry of Science and Education of the Republic of Azerbaijan, AZ 1025, 30 Khojaly str., Baku, Azerbaijan.
Ayaz M MammadovAcademician Y.H. Mammadaliyev Institute of Petrochemical Processes of the Ministry of Science and Education of the Republic of Azerbaijan, AZ 1025, 30 Khojaly str., Baku, Azerbaijan.
Imren BayilDepartment of Bioinformatics and Computational Biology, Gaziantep University, Gaziantep, Turkey.
Sevda A MuradovaDepartment of Medical Microbiology and Immunology, Azerbaijan Medical University, AZ1022, 14 A. Qasimzade str, Baku, Azerbaijan.
Nabila DjadiLaboratory of Materials Chemistry, University of Mentouri Brothers Constantine, Constantine, Algeria.
Taha AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, 62529, Abha, Saudi Arabia.
Al-Anood M Al-DiesDepartment of Chemistry, Al-Qunfudah University College, Umm Al-Qura University, Makkah, Saudi Arabia.
Yayesew Amlaku ZerihunDepartment of Chemistry, College of Science, Bahir Dar University, P. O. Box 79, Bahir Dar, Ethiopia. dryayesewamlakuzerihun@gmail.com.
Abdelkrim GuendouziLaboratory of Chemistry, Synthesis, Properties and Applications, University of Saïda, Saïda, Algeria.
Magdi E A ZakiDepartment Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), 11623, Riyadh, Saudi Arabia. mezaki@imamu.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, three imidazole derivatives : 2,4,5-triphenyl-1-(4-(phenyldiazenyl)phenyl)-1 H-imidazole (N1), 2-(4-chlorophenyl)-4,5-diphenyl-1-(4-(phenyldiazenyl)phenyl)-1 H-imidazole (N2), and 2-(2,4-dichlorophenyl)-4,5-diphenyl-1-(4-(phenyldiazenyl)phenyl)phenyl)-1 H-imidazole (N3), which were prepared using N-methyl-2-pyrrolidone hydrogen sulfate ionic liquid as a catalyst, were selected for detailed evaluation. The antimicrobial activities of these compounds were assessed against a panel of pathogenic microorganisms, including Gram-positive bacteria (Staphylococcus aureus, Bacillus anthracoides), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae), and the fungal strain Candida albicans. The Density Functional Theory (DFT) results showed that the N3 molecule exhibited the highest stability with the largest ΔEgap (2.9546 eV) and chemical hardness, while N1 showed the highest reactivity. Frontier molecular orbital (FMO) and electrostatic potential (ESP) analyses revealed that the HOMO orbitals are delocalized over the imidazole ring and neighboring aromatic fragments, and the LUMO orbitals are spread over the phenyldiazenyl phenyl fragments. A comparative analysis suggests that while N3 is the most chemically stable, N2 demonstrates the highest potential for biological activity, consistent with experimental antimicrobial results. Both in-vitro and in-silico results revealed that the N2 molecule exhibits superior biological activity compared to N1 and N3. Molecular docking studies of N2 were performed with its target protein to explore its binding interactions with several amino acid residues, elucidating its potential antioxidant mechanism. Docking results revealed that all ligands exhibit strong binding affinities, with N1 showing the highest MolDock score and N2 demonstrating strong specificity through key hydrogen bonding and π-interactions. Molecular dynamics simulations, including RMSD, RMSF, radius of gyration (Rg), solvent-accessible surface area (SASA), and principal component analysis (PCA), further confirmed the structural stability and dynamic behavior of the protein-ligand complexes. MMPBSA binding free energy calculations indicated that N2@1AI9 forms the most stable complex, primarily driven by favorable van der Waals and electrostatic interactions. In silico ADMET analysis suggests all compounds, particularly the lead compound N2, face challenges with high lipophilicity, low solubility, and predicted drug-drug interaction risk (CYP2C19 inhibition for all; CYP3A4 and P-gp substrate for N2), yet their lack of BBB permeation supports their further development, especially for topical or intravenous use. Overall, the results suggest that N2 is a promising candidate for further development as a potential antimicrobial anti-fungal agent targeting the ergosterol biosynthesis pathway in Candida albicans.

Indexed as

Anti-Infective AgentsImidazolesBiosynthetic PathwaysCandida albicansDensity Functional TheoryDrug DevelopmentErgosterolGram-Negative BacteriaGram-Positive BacteriaMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationAnti-Infective AgentsErgosterolimidazoleImidazolesAntimicrobial activityDFTImidazoleMolecular dockingMolecular dynamics

Identifiers

PMID41152498
PMCPMC12569038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.